Bank of America Securities analyst Travis Steed has maintained their bullish stance on ABT stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Travis Steed has given his Buy rating due to a combination of factors that highlight Abbott Laboratories’ strong performance and growth potential. The company’s third-quarter results were generally in line with expectations, showing a 7.5% revenue growth excluding COVID-19 impacts and an earnings per share of $1.30. Abbott has reiterated its revenue growth guidance for 2025, projecting a 7.5-8% increase excluding COVID-19, and 6-7% including it. The earnings per share guidance for 2025 has been maintained at a midpoint range of $5.12-$5.18, indicating steady financial health.
Additionally, the company’s operational margin is expected to remain stable at around 23.5%, and it is anticipated that Abbott will meet the market’s 2026 growth estimates of 7.5% revenue growth and 10% EPS growth. Despite some challenges in the nutrition segment, other areas like devices have shown stronger-than-expected growth. With segments such as Cardiac Rhythm Management and Electrophysiology outperforming expectations, Abbott is seen as a high-quality, defensive company with robust growth prospects in the medtech sector.
According to TipRanks, Steed is a 4-star analyst with an average return of 6.0% and a 56.68% success rate. Steed covers the Healthcare sector, focusing on stocks such as Boston Scientific, Intuitive Surgical, and Medtronic.